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Genetic testing for germline-BRCA1/BRCA2 mutations in epithelial ovarian cancer (EOC) was 
commissioned by NHS-England in 2015 following the drop in BRCA-testing threshold to 10% carrier 
probability.  EOC BRCA-carriers can benefit from targeted therapy such as poly-ADP-ribose-
polymerase inhibitors (PARP-i) which improve survival in recurrent disease.  Additionally, downstream 
predictive/cascade-testing enables unaffected at-risk mutation carriers to access opportunities of 
screening and chemoprevention (selective-estrogen-receptor-modulators) for breast cancer (BC), or 
surgical prevention (risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy) to 
reduce their BC and/or ovarian cancer (OC) risks. Unaffected women can also benefit from lifestyle 
and reproductive advice incorporating breast-feeding, contraception and informed reproductive 
decision-making, including preimplantation genetic-diagnosis. In this BJOG issue, Rust et al report on 
the Scottish BRCA-testing experience in unselected EOC (Rust BJOG; 2018). Their findings are 
reassuring, in line with the established literature and reconfirm the importance of offering genetic-
testing to all women (irrespective of age) with non-mucinous high-grade EOC. Although they tested 
women with low-grade disease too, BRCA-mutations are not associated with low-grade EOC and these 
women can be excluded. The 13% mutation rate in their prevalent sub-group highlights the 
importance of testing all women under follow-up too. Unselected BRCA-testing in high-grade EOC is 
cost-effective (Eccleston ValueHealth.2017;20(4):567-576) and identifies 50% additional carriers 
compared to earlier family-history/clinical-criteria based testing (George, SciRep.2016;6:29506, Rust 
BJOG;2018). This offers a precision-medicine approach to reduce the burden of BRCA-associated 
cancers in the population. A number of delivery models founded on local solutions/contexts have been 
used to successfully implement this strategy with high uptake and patient acceptability: traditional 
Clinical-Genetics model (e.g. West-Scotland, Guys-Hospital), Mainstreaming (Medical-oncology 
driven: e.g. Royal-Marsden, East-Scotland), Genetics Co-ordinated (e.g. Cambridge/East-of-England) 
and Cancer-MDT coordinated (Surgical/Medical/Clinical-oncology driven: e.g. Barts-Health).  
 
Newer intermediate-risk OC genes (RAD51C/RAD51D/BRIP1) are associated with OC-risks of 5.8%-
11%. RRSO is cost-effective and now recommended for women at >5% OC-risk thus providing clinical 
utility for testing RAD51C/RAD51D/BRIP1 mutations too (Manchanda, J Med Genet:2016;53(9):591-
9). Additionally these mutations affect the homologous recombination repair pathway leading to a 
functional “BRCA-ness” tumour and are likely to respond to PARP-i (Mirza NEng JMed 2016;375:2154-
64).  Although the authors undertook RAD51C/RAD51D testing, this was in part restricted to women 
with strong family-history, which may be suboptimal at identifying carriers. Somatic BRCA-mutations 
occur in around 7% of EOC. These women also benefit from PARP-i in terms of improved survival 
following recurrence.  The introduction of Olaparib/Rucaparib into clinical practice and availability of 
other PARP-i trials, suggests clinical utility in offering somatic BRCA-testing too, although its cost-
effectiveness needs confirmation. Robust concordance data for germline and somatic mutation 
testing are currently lacking and need establishing. We recommend germline 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 panel-testing and somatic-BRCA1/BRCA2 testing for all high-
grade EOC. The satisfaction/regret, quality-of-life and cost-effectiveness with this approach is being 
evaluated in the SIGNPOsT study (ISRCTN-16988857). Future therapeutic/technological developments 
including homologous recombination deficiency assays and stratified medicine approaches will 
warrant testing to be undertaken soon after diagnosis to deliver a personalised targeted precision-
medicine strategy for OC therapy. Given the limited awareness and small proportion of at-risk carriers 
identified in the population to date, this will also provide much needed impetus for earlier 
identification of unaffected carriers and consequent OC/BC prevention. 
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